How to buy Immuron stock

Immuron Limited is a biotechnology business based in the US. Immuron shares (IMRN) are listed on the NASDAQ and all prices are listed in US Dollars.

Immuron share price

Use our graph to track the performance of IMRN stocks over time.

Immuron shares at a glance

• Key figures

Information last updated 2021-04-30.

52-week range	$1.81 - $15.60
50-day moving average	$5.91
200-day moving average	$6.81
Wall St. target price	$6.41
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.68

Buy Immuron shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Immuron stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Immuron Limited by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Immuron financials

Revenue TTM	$982,252
Gross profit TTM	$1.8 million
Return on assets TTM	-21.43%
Return on equity TTM	-40.38%
Profit margin	0%
Book value	$5.04
Market capitalisation	$30.8 million

TTM: trailing 12 months

Shorting Immuron shares

There are currently 343 Immuron shares held short by investors – that's known as Immuron's "short interest". This figure is 11333.3% up from 3 last month.

There are a few different ways that this level of interest in shorting Immuron shares can be evaluated.

Immuron's "short interest ratio" (SIR)

Immuron's "short interest ratio" (SIR) is the quantity of Immuron shares currently shorted divided by the average quantity of Immuron shares traded daily (recently around 17150). Immuron's SIR currently stands at 0.02. In other words for every 100,000 Immuron shares traded daily on the market, roughly 20 shares are currently held short.

However Immuron's short interest can also be evaluated against the total number of Immuron shares, or, against the total number of tradable Immuron shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Immuron's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Immuron shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Immuron shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Immuron.

Find out more about how you can short Immuron stock.

Immuron share dividends

We're not expecting Immuron to pay a dividend over the next 12 months.

Immuron share price volatility

Over the last 12 months, Immuron's shares have ranged in value from as little as $1.81 up to $15.6. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Immuron's is 1.876. This would suggest that Immuron's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Immuron overview

Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia. .

Frequently asked questions

• What percentage of Immuron is owned by institutions?

  Currently 3.593% of Immuron shares are held by institutions.

• When does the fiscal year end for Immuron?

  Immuron's fiscal year ends in June.

• Where is Immuron based?

  Immuron's address is: 62 Lygon Street, Carlton, VIC, Australia, 3053

• What is Immuron's ISIN number?

  Immuron's international securities identification number is: US45254U1016

• What is Immuron's CUSIP number?

  Immuron's Committee on Uniform Securities Identification Procedures number is: 45254U101